In a report released on July 17, Matt Hewitt from Craig-Hallum maintained a Buy rating on Codexis. The company’s shares closed last Friday at $2.24. Unlock powerful investing tools with TipRanks ...
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two ...
Ovid Therapeutics shook up its leadership, including by promoting Charles Carter to the role of finance chief and hiring Kevin Norrett as chief business officer, as the biopharmaceutical company ...
Codexis (CDXS) stock outlook | valuation trends and trading momentum remain in focus. Codexis Inc. (CDXS) closed at $2.36, ...
Codexis, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where shareholders elected directors Stephen G. Dilly, Raymond De Vré and Rahul Singhvi to three-year terms expiring at the ...
Greetings, and welcome to the Codexis Report 2026 Q1 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce Georgia Erbez, Chief ...
Image source: The Motley Fool. Codexis (NASDAQ:CDXS) reported a marked reduction in net loss and strong revenue growth, primarily from the full recognition of Merck technology transfer revenue. The ...
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Codexis Inc. (CDXS) on Thursday reported a loss of $8.7 million in its first quarter. On a per-share basis, the Redwood City, California-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results